PATENT

UTILITY PATENT APPLICATION TRANSMITTAL

(only for new non-provisional applications under 37 CFR §1.53(b))

	*						21
Com	nmiss	Patent Application ioner of Patents 1450					
	andri	a, VA 22313-1450	I he dep Exp Pate	ereby ce osited woress Mai	rtify that this ith the United I in an envelor ication, Commudexandria, VA	corresponden States Postal e addressed t	ce is bei Service Mail St atents P
Sir:			Box	(1450, A			on
		ed herewith for filing is the patent applicatio CFR 1.53(b) of:		e of Defice nature	July 3, 200	Mena	3
	ENTO	DOCKET NO.: USAV2003/0110 US NP ORS: Tahir N. Majid, et al Pyrazolisoquinolines as Kinase Inhibitors for the Treatment of Variou Disorders		oress Mai	El 816576: 1 No.	588 US	
APP	LICA	TION ELEMENTS					· .
1.	\boxtimes	*Fee Transmittal Form (e.g., PTO/SB/17) (Submit an original and a duplicate for fee processing)					
2.		Specification (preferred arrangement set forth below) - Descriptive title of the Invention - Cross References to Related Applications - Statement Regarding Fed sponsored R & D - Reference to Microfiche Appendix - Background of the Invention - Brief Summary of the Invention - Brief Description of the Drawings (if filed) - Detailed Description - Claim(s) - Abstract of the Disclosure	Total Pag	ges	104		
3.		Drawing(s) (35 U.S.C. 113)	Total She	eets			
4.	Oath a.	or Declaration Newly unexecuted (original or copy)	Total Pag	jes	2		,
•	b.	Copy from a prior application (37 CFR §	1.63(d))				
		i. DELETION OF INVENTOR(S) Signed statement attached deleting application, see 37 CFR §§ 1.63(d)			ed in the p	rior	
5.	Powe	er of Attorney Newly executed (original)	Total Pag	ies	1		
-	b.	Copy from a prior application (37 CFR §	1.63(d))				

Microfiche Computer Program (Appendix)

Page 2 7. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) Computer Readable Copy Paper Copy (identical to computer copy) b. Statement verifying identity of above copies If a CONTINUING Application, check appropriate box, and supply the requisite information: Continuation-in-part Divisional Continuation of prior application no: ____ _, filed _ Examiner , Group/Art Unit (The cross reference has been/will be inserted on page one of the specification). This application claims the benefit of U.S. Provisional Application No. filed . (The cross reference has been/will be inserted on page one of the specification). Incorporation By Reference (useable if filing a continuation/divisional and a copy of the declaration from the prior application is enclosed.) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein. ACCOMPANYING APPLICATION PARTS Assignment Papers (cover sheet & document(s)) 37 CFR §3.73(b) Statement 8. (when there is an assignee) Verified English Translation Document (if applicable) 9. Information Disclosure Copies of IDS Citations 10. Statement (IDS)/PTO-1449 **Preliminary Amendment** 11. Return Receipt Postcard (MPEP 503) 12. (Should be specifically itemized) *Small Entity Statement(s) Statement filed in prior application, 13. Status still proper and desired (PTO/SB/09-12) Certified Copy of Priority Document(s) (if foreign priority is claimed) Other: Application Data Sheet 15. CORRESPONDENCE ADDRESS **Customer Number or Bar Code Label** PATENT TRADEMARK OFFICE Balaram Gupta, Reg. No. 40,009 Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-3364
Telefax (908) 231-2626
Aventis Docket No. USAV2003/0110 US NP

Application Transmittal Letter

Approved for use through 04/30/2003. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

F	E	E	1	R	A	N	S	M	IT	T	Al	L
•			fc	r	F	Y	2	00)3			

Patent fees are subject to annual revision. Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT

(\$) 906.00

C	Complete if Known
Application Number	N t Yet Assigned
Filing Date	Concurrently Filed Her with
First Named Inventor	Tahir N. Majid, et al
Examiner Name	
Group / Art Unit	
Attorney Docket No.	USAV2003/0110 US NP

METHOD OF PAYMENT (check all that apply)	FEE CALCULATION (continued)					
Check Credit Card Money Other None	3. AL	DITIO	NAL FE	ES		
Order	Large Er	ntity 1	Small Er	ıtitv		1
Deposit Account	Fee	Fee	Fee	Fee		
Deposit Account 18-1982	Code	(\$)	Code	(\$)		
Number L					Fee Description Fee	Paid
Account Aventis Pharmaceuticals Inc.	1051	130	2051	65	Surcharge - late filing fee or oath	
The Commissioner is authorized to: (check all that apply)		· ·			Surcharge - late provisional filing fee or	
Charge fee(s) indicated below Credit any overpayments	1052 1053	50 130	2052 1053	25 130	cover sheet Non-English Specification	
Charge any additional fee(s) during the pendency of this application	1812	2,520	1812	2,520	For filing a request for reexamination	
Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account	1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
FEE CALCULATION	1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1. BASIC FILING FEE	1251	110	2251	55	Extension for reply within first month	
Large Entity Small Entity Fee	4050		0050		Estancian for confusithin accord worth	
Fee Fee Fee Fee Fee Description Paid Code (\$) Code (\$)	1252	410	2252	205	Extension for reply within second month	
1001 750 2001 375 Utility filing fee 750	1253	930	2253	465	Extension for reply within third month	
1002 330 2002 165 Design filing Fee	1254	1,450	2254	725	Extension for reply within fourth month	
1003 520 2003 260 Plant filing fee	1255	1970	2255	985	Extension for reply within fifth month	-
1004 750 2004 375 Reissue filing fee	1401	320	2401	160	Notice of Appeal	
1005 160 2005 80 Provisional filing fee	1402	320	2402	160	Filing a brief in support of an appeal	
SUBTOTAL (1) (\$) 750.00	1403	280	2403	140	Request for oral hearing	
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE	1451	1,510	1451	1,510	Petition to institute a public use proceeding	
Fee Extra from Fee	1452	110	2452	55	Petition to revive - unavoidable	
Extra from Fee Claims below Paid						
Total Claims 24 -20**= 4 x 18 = 72	1453	1,300	2453	650	Petition to revive - unintentional	
Independent 4 - 3**= 1 x 84 = 84	1501	1,300	2501	650	Utility issue fee (or reissue)	
Claims	1502	470	2502	235	Design issue fee	
Multiple Dependent 0 = 0	1503	630	2503	315	Plant issue fee	
Laura Salita Compil Salita	1460 1807	130 50	1460 1807	130 50	Petitions to the Commissioner Petitions related to provisional	
Large Entity Small Entity Fee Fee Fee Fee	1607	.30	1007	30	applications	
Code (\$) Code (\$) Fee Description	1806	180	1806	180	Submission of Information Disclosure	
1202 18 2202 9 Claims in excess of 20	1800	100	1000	100	Stmt	
1201 84 2201 42 Independent claims in excess of 3	8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1203 280 2203 140 Multiple dependent claim, if not paid	1809	750	2809	375	Filing a submission after final rejection (37 CFR § 1.129(a))	
1204 84 2204 42 **Reissue independent claims over original patent	1810	750	2810	375	For each additional invention to be examined (37 CFR § 1.129(b))	
1205 18 2205 9 **Reissue claims in excess of 20 and over original patent	1801	750	2801	375	Request for Continued Examination (RCE)	
	1802	900	1802	900	Request for expedited examination of a design application	
SUBTOTAL (2) (\$) 156.00	Other fee	(specify)				
**or number previously paid, if greater; For Reissues, see above	*Reduce	d by Basic	Filing Fee	Paid	SUBTOTAL (3) (5)	
COUNTRY DV				Complete (If applicable)		
SUBMITTED BY		T 6			Complete (If applicable)	—

Balaram Gupta, Reg. No. 40,009 40,009 Telephone (908) 231-3364 Name (Print/Type) Signature

> WARNING: Information on this form may becom public. Credit card information sh uld not be included on this form. Provide credit card information and authorization n PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Alexandria, VA 22313. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria,